Comparison Between the Efficacy of SGLT2 Inhibitor Therapy Versus ACE Inhibitor in the Treatment of Diabetic Kidney Disease

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 212 participants.

Also called NCT05373004

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose prevention
Phase
Phase 2/3
Enrolled
  • 212 participants (planned count) (from the registry)
Sponsor
Omar Tarek Elfarargi (from the registry)
Registry
  • NCT NCT05373004
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05373004. Randomized; double masking; primary purpose prevention. Start 2023-03 (anticipated); primary completion 2024-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison Between the Efficacy of SGLT2 Inhibitor Therapy Versus ACE Inhibitor in the Treatment of Diabetic Kidney Disease
Acronym
SGLT2i VS ACEi
Condition
Diabetic Nephropathy Type 2
Intervention (Drug)
Empagliflozin 25 MG
Intervention (Drug)
Enalapril Maleate 20 mg
Lead sponsor
Omar Tarek Elfarargi (class: other government)

Record details

Record id
cardio:ct-nct05373004
Content hash
45c78968da8945757344bf9de8bd372b57736d5fc32774e72df8a354d6f7469e